
PRCT Stock Forecast & Price Target
PRCT Analyst Ratings
Bulls say
PROCEPT BioRobotics Corp has demonstrated a consistent growth trend in utilization, with an average increase of approximately 6.1% per quarter over the last six quarters, signaling rising demand for its surgical robotic systems. The company is also effectively managing its operating expenses, committing to grow these costs at half the rate of its top-line growth, which suggests a clear pathway to profitability. Additionally, strong performance in capital system placements, with 58 new systems installed in the recent quarter—outpacing prior guidance—highlights the company’s robust market presence and future growth potential.
Bears say
PROCEPT BioRobotics's stock has experienced a significant decline of approximately 54% year-to-date, indicating a lack of confidence among investors despite the company's ability to exceed its internal guidance. The company faces multiple downside risks, including a potential decrease in demand for capital equipment, reduced usage of handpieces by customers, heightened competitive pressures, and unfavorable changes in reimbursement rates for its Aquablation therapy. Additionally, commentary regarding utilization and inventory has contributed to further negative sentiment, suggesting ongoing challenges that may impact future revenue growth.
This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.
PRCT Analyst Forecast & Price Prediction
Start investing in PRCT
Order type
Buy in
Order amount
Est. shares
0 shares